Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013-2014 at the Geneva University Hospitals

Autor: Diego O. Andrey, Jacques Schrenzel, Patrice Francois, C. Manzano, Adriana Renzoni, William L. Kelley, Stéphan Juergen Harbarth, Eve-Julie Bonetti
Jazyk: angličtina
Rok vydání: 2017
Předmět:
0301 basic medicine
Microbiology (medical)
Methicillin-Resistant Staphylococcus aureus
Italy/epidemiology
Genotype
medicine.drug_class
Penicillin-Binding Proteins/genetics
030106 microbiology
Antibiotics
Cephalosporin
Drug resistance
Microbial Sensitivity Tests
medicine.disease_cause
Staphylococcal infections
Microbiology
Anti-Bacterial Agents/pharmacology
Hospitals
University
03 medical and health sciences
Minimum inhibitory concentration
Bacterial Proteins
Drug Resistance
Bacterial
medicine
Prevalence
Penicillin-Binding Proteins
Humans
ddc:616
Methicillin-Resistant Staphylococcus aureus/classification/drug effects/genetics/isolation & purification
business.industry
Bacterial Proteins/genetics
General Medicine
Staphylococcal Infections
Antimicrobial
medicine.disease
Methicillin-resistant Staphylococcus aureus
3. Good health
Anti-Bacterial Agents
Cephalosporins
Molecular Typing
Infectious Diseases
Italy
Staphylococcus aureus
Mutation
Original Article
Cephalosporins/pharmacology
business
Staphylococcal Infections/epidemiology/microbiology
Zdroj: European Journal of Clinical Microbiology & Infectious Diseases, Vol. 36, No 2 (2017) pp. 343-350
European journal of clinical microbiology & infectious diseases : official publication of the Europe
European Journal of Clinical Microbiology & Infectious Diseases
ISSN: 0934-9723
Popis: Ceftaroline is a broad-spectrum antibiotic with activity against methicillin-resistant Staphylococcus aureus (MRSA) strains. Ceftaroline susceptibility of an MRSA set archived between 1994 and 2003 in the Geneva University Hospitals detected a high percentage (66 %) of ceftaroline resistance in clonotypes ST228 and ST247 and correlated with mutations in PBP2a. The ceftaroline mechanism of action is based on the inhibition of PBP2a; thus, the identification of PBP2a mutations of recently circulating clonotypes in our institution was investigated. We analyzed ceftaroline susceptibility in MRSA isolates (2013 and 2014) and established that resistant strains correlated with PBP2a mutations and specific clonotypes. Ninety-six MRSA strains were analyzed from independent patients and were isolated from blood cultures (23 %), deep infections (38.5 %), and superficial (skin or wound) infections (38.5 %). This sample showed a ceftaroline minimum inhibitory concentration (MIC) range between 0.25 and 2 μg/ml and disk diameters ranging from 10 to 30 mm, with a majority of strains showing diameters ≥20 mm. Based on the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints, 76 % (73/96) of isolates showed susceptibility to ceftaroline. Nevertheless, we still observed 24 % (23/96) of resistant isolates (MIC = 2 μg/ml). All resistant isolates were assigned to clonotype ST228 and carried the N146K mutation in PBP2a. Only two ST228 isolates showed ceftaroline susceptibility. The decreasing percentage of ceftaroline-resistant isolates in our hospital can be explained by the decline of ST228 clonotype circulating in our hospital since 2008. We present evidence that ceftaroline is active against recent MRSA strains from our hospital; however, the presence of PBP2a variants in particular clonotypes may affect ceftaroline efficacy.
Databáze: OpenAIRE
Externí odkaz: